Virologist Kelly Warfield appointed R&D President at Sabin Vaccine Institute, focusing on Marburg and Sudan ebolavirus vaccines.

Kelly Warfield, an accomplished virologist and vaccine development leader, has been appointed as Research & Development President at the Sabin Vaccine Institute. She will lead the R&D program, working with the Board of Trustees and CEO Amy Finan to drive the organization's strategic vision. Warfield previously managed a 300-scientist team at Emergent BioSolutions and will focus on advancing Sabin's candidate vaccines against Marburg and Sudan ebolavirus towards licensure.

August 20, 2024
6 Articles